Company Description
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.
The company was founded in 2004 and is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 183 |
| CEO | Dr. Laura E. Niklason M.D., Ph.D. |
Contact Details
Address: 2525 East North Carolina Highway 54 Durham, North Carolina 27713 United States | |
| Phone | 919-313-9633 |
| Website | humacyte.com |
Stock Details
| Ticker Symbol | HUMA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001818382 |
| CUSIP Number | 44486Q103 |
| ISIN Number | US44486Q1031 |
| Employer ID | 85-1763759 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Laura E. Niklason M.D., Ph.D. | Founder, President, Chief Executive Officer and Director |
| Dale A. Sander | Chief Financial Officer, Chief Corporate Development Officer and Treasurer |
| Dr. Shamik J. Parikh M.D. | Chief Medical Officer |
| Dr. Juliana L. Blum Ph.D. | Co-Founder and Executive Advisor |
| Dr. Heather Ledbetter Prichard Ph.D. | Chief Operating Officer |
| Sabrina Osborne | Executive Vice President of Business Strategy and People |
| William John Scheessele | Chief Commercial Officer |
| Harold Alterson | Senior Vice President of Quality |
| Dr. Yang Cao M.D., Ph.D. | Chief Regulatory Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 8, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 7, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 4, 2024 | 8-K | Current Report |
| Mar 1, 2024 | 424B5 | Filing |
| Feb 29, 2024 | 424B5 | Filing |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 9, 2024 | 8-K | Current Report |